First Drug to Fix Genetic Obesity's Root Cause Enters Human Trials

Clarissa Desjardins is taking another shot.

Congruence Therapeutics, the Montreal biotech she founded in 2021, has moved its lead drug into Phase 1 trials for MC4R-deficient genetic obesity, as first reported by Endpoints News. The company confirmed the trial milestone alongside a financing the publication put at $40 million — though public filings show only a $32 million round closed in September 2025. Congruence did not respond to a request for clarification on the total raise figure.

The science is the more interesting part. CGX-926 is a small-molecule pharmacological corrector — a drug designed to stabilize misfolded MC4R proteins, rescue them from being degraded inside the cell, and restore normal receptor signaling. MC4R sits in the hypothalamus and regulates hunger, energy expenditure, and body weight. When the receptor is folded incorrectly due to a genetic mutation, it gets trapped in the endoplasmic reticulum and never reaches the cell surface. The result is relentless hunger, hyperphagia, early-onset obesity, and no approved treatment that addresses the root cause.

CGX-926 is designed to fix that. In animal models, the drug reduced body weight and hyperphagia, restoring signaling to levels comparable to wild-type receptors. Congruence's computational platform, called Revenir, identifies allosteric pockets on mutant proteins and screens for small molecules that can exploit them — essentially looking for the exact structural handle needed to rescue a misfolded receptor. It is a different bet than GLP-1 agonists, which are effective at reducing appetite but work through a completely different mechanism and do not address the underlying genetic defect.

The commercial logic is also distinct. MC4R-deficient obesity is rare — estimated to affect roughly 1–2.5% of individuals with severe early-onset obesity — but it is genetically validated, homogeneous, and has zero approved therapies targeting the root cause. A patient who responds to CGX-926 would likely need the drug for life, creating a durable revenue opportunity in a compact population. Congruence is also applying the same corrector approach to GBA1-driven Parkinson's disease and Alpha-1 antitrypsin deficiency, both diseases of protein misfolding with high unmet need.

Desjardins is a known quantity in Montreal biotech. Her previous company, Clementia Pharmaceuticals, developed palovarotene for fibrodysplasia ossificans progressiva — a rare disease in which soft tissues progressively turn to bone. She ran Clementia from 2011 until Ipsen acquired it in April 2019 for $1.3 billion. The acquisition was a landmark for Canadian biotech. Congruence is her fourth company.

The September financing included Amplitude Ventures, Lumira, Investissement Quebec, BDC Capital's Thrive Venture Fund, OrbiMed, Driehaus, Silver Arc, and Alexandria. The company previously raised a $50 million Series A in 2022, later extended to over $65 million total.

Phase 1 will first test CGX-926 in healthy volunteers before moving to an efficacy cohort in patients with confirmed MC4R-d mutations. Proof-of-concept data is expected before the end of 2026. That timeline matters: the obesity drug landscape is shifting fast, and by the time CGX-926 reads out, Wegovy and Mounjaro will be even more entrenched in clinical guidelines. The differentiation story — genetic cause, oral delivery, life-long treatment — will need to be airtight.